


Status: Currently Official on 16-Feb-2025  
Official Date: Official as of 01-Jan-2022  
Document Type: USP Monographs  
DocId: GUID-876D6F7C-1A36-4E19-80CA-F66784E53476\_6\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M68470\\_06\\_01](https://doi.org/10.31003/USPNF_M68470_06_01)  
DOI Ref: fhh11

© 2025 USPC  
Do not distribute

## Prazosin Hydrochloride



$C_{19}H_{21}N_5O_4 \cdot HCl$  419.86

Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-, monohydrochloride;

1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine monohydrochloride CAS RN®: 19237-84-4; UNII: X0Z7454B90.

### DEFINITION

Prazosin Hydrochloride contains NLT 97.0% and NMT 103.0% of prazosin hydrochloride ( $C_{19}H_{21}N_5O_4 \cdot HCl$ ), calculated on the anhydrous basis.

### IDENTIFICATION

- **A. SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy:** 197K or 197A
- **B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **C.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.
- **D. IDENTIFICATION TESTS—GENERAL (191), Chemical Identification Tests, Chloride:** Meets the requirements

### ASSAY

#### PROCEDURE

[CAUTION—Care should be taken to prevent inhaling particles of Prazosin Hydrochloride and to prevent its contacting any part of the body.]

**Mobile phase:** [Methanol](#), [glacial acetic acid](#), and [water](#) (700:10:300). Add 0.2 mL of diethylamine to 1 L of *Mobile phase* such that the retention time of prazosin hydrochloride is 6–10 min.

**Diluent:** [Methanol](#) and [water](#) (70:30)

**Standard stock solution:** 1 mg/mL of [USP Prazosin Hydrochloride RS](#) in [methanol](#)

**Standard solution:** 30 µg/mL of [USP Prazosin Hydrochloride RS](#) in *Diluent* from the *Standard stock solution*

**Sample stock solution:** 1 mg/mL of Prazosin Hydrochloride in [methanol](#)

**Sample solution:** 30 µg/mL of Prazosin Hydrochloride in *Diluent* from *Sample stock solution*

#### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.

**Column:** 4.6-mm × 25-cm; 5-µm packing L3

**Flow rate:** Adjusted to obtain a retention time of 6–10 min for prazosin

**Injection volume:** 5 µL

**Run time:** NLT 2 times the retention time of the prazosin peak

#### System suitability

**Sample:** *Standard solution*

#### Suitability requirements

**Tailing factor:** NMT 2.0

**Relative standard deviation:** NMT 1.10%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of prazosin hydrochloride ( $C_{19}H_{21}N_5O_4 \cdot HCl$ ) in the portion of Prazosin Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of prazosin from the *Sample solution*

$r_S$  = peak response of prazosin from the *Standard solution*

$C_S$  = concentration of [USP Prazosin Hydrochloride RS](#) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Prazosin Hydrochloride in the *Sample solution* (µg/mL)

**Acceptance criteria:** 97.0%–103.0% calculated on the anhydrous basis

## IMPURITIES

### • [RESIDUE ON IGNITION \(281\)](#)

**Sample:** 1 g of Prazosin Hydrochloride

**Acceptance criteria:** NMT 0.4%

[NOTE—Save the residue for the test for *Iron*.]

### • IRON

**Standard stock solution:** Dissolve 100 mg of iron wire in 10 mL of [hydrochloric acid](#) with the aid of boiling. Cool, transfer to a 1000-mL volumetric flask, and dilute with [water](#) to volume.

**Standard solution:** 4.0 µg/mL of iron in 0.2 N [nitric acid](#) from *Standard stock solution*

**Sample solution:** Dissolve the residue obtained in the test for *Residue on Ignition* in 20 mL of 2 N [nitric acid](#). Slowly evaporate this solution to approximately 5 mL; transfer to a 25-mL volumetric flask, using 0.2 N [nitric acid](#) as a wash solvent; and dilute with 0.2 N [nitric acid](#) to volume.

### Instrumental conditions

(See [Atomic Absorption Spectroscopy \(852\)](#).)

**Mode:** Atomic absorption

**Analytical wavelength:** 248 nm

**Lamp:** Iron hollow-cathode

**Flame:** Air–acetylene

**Blank:** [Water](#)

**Analysis:** Determine the absorbances of the *Standard solution* and the *Sample solution* against the *Blank*.

**Acceptance criteria:** The absorbance of the *Sample solution* is NMT that of the *Standard solution* (0.010%).

### • NICKEL

**Standard stock solution:** Dissolve 100 mg of nickel in 10 mL of [nitric acid](#) with the aid of boiling. Cool, transfer to a 1000-mL volumetric flask, and dilute with [water](#) to volume.

**Standard solution:** 4.0 µg/mL of nickel in 0.2 N [nitric acid](#) from *Standard stock solution*

**Sample solution:** Prepare as directed in the test for *Iron*.

### Instrumental conditions

(See [Atomic Absorption Spectroscopy \(852\)](#).)

**Mode:** Atomic absorption

**Analytical wavelength:** 232 nm

**Lamp:** Nickel hollow-cathode

**Flame:** Air–acetylene

**Blank:** [Water](#)

**Analysis:** Determine the absorbances of the *Standard solution* and the *Sample solution* against the *Blank*.

**Acceptance criteria:** The absorbance of the *Sample solution* is NMT that of the *Standard solution* (0.010%).

### Change to read:

### • ORGANIC IMPURITIES

**Buffer:** 3.48 g/L of [sodium pentanesulfonate](#) and 3.64 g/L of [tetramethylammonium hydroxide](#). Adjust with [glacial acetic acid](#) to a pH of 5.0.

**Mobile phase:** [Methanol](#) and *Buffer* (500:500)

**System suitability solution:** 0.032 mg/mL of [USP Metoclopramide Hydrochloride RS](#) and 0.004 mg/mL of [USP Prazosin Hydrochloride RS](#) in *Mobile phase*

**Standard solution:** 1 µg/mL of [USP Prazosin Hydrochloride RS](#) in *Mobile phase*

**Sensitivity solution:** ▲0.5▲ (ERR 1-Jan-2022) µg/mL of [USP Prazosin Hydrochloride RS](#) in *Mobile phase* from the *Standard solution*

**Sample solution:** 1 mg/mL of Prazosin Hydrochloride in *Mobile phase*

#### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4.6-mm × 25-cm; 5-μm packing [L1](#)

**Flow rate:** 1 mL/min

**Injection volume:** 20 μL

**Run time:** NLT 6 times the retention time of the prazosin peak

#### System suitability

**Samples:** *System suitability solution*, *Standard solution*, and *Sensitivity solution*

[NOTE—The relative retention times of metoclopramide and prazosin are 0.55 and 1.00, respectively.]

#### Suitability requirements

**Resolution:** NLT 8 between the metoclopramide and prazosin peaks, *System suitability solution*

**Relative standard deviation:** NMT 2.0%, *Standard solution*

**Signal-to-noise ratio:** NLT 10, *Sensitivity solution*

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of each individual impurity in the portion of Prazosin Hydrochloride taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of each individual impurity from the *Sample solution*

$r_S$  = peak response of prazosin from the *Standard solution*

$C_S$  = concentration of [USP Prazosin Hydrochloride RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Prazosin Hydrochloride in the *Sample solution* (mg/mL)

#### Acceptance criteria

**Each individual impurity:** NMT 0.2%

**Total impurities:** NMT 0.5%. The reporting threshold is 0.05%.

#### SPECIFIC TESTS

- [WATER DETERMINATION \(921\)](#), [Method I](#)

**Anhydrous form:** NMT 2.0%

**Polyhydrate form:** 8.0%–15.0%

#### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers.
- **LABELING:** Label it to indicate whether it is anhydrous or is the polyhydrate.
- **USP REFERENCE STANDARDS (11).**  
[USP Metoclopramide Hydrochloride RS](#)  
[USP Prazosin Hydrochloride RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question             | Contact                                                                     | Expert Committee          |
|----------------------------|-----------------------------------------------------------------------------|---------------------------|
| PRAZOSIN HYDROCHLORIDE     | <a href="#">Documentary Standards Support</a>                               | SM22020 Small Molecules 2 |
| REFERENCE STANDARD SUPPORT | RS Technical Services<br><a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a> | SM22020 Small Molecules 2 |

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. 45(4)

**Current DocID: GUID-876D6F7C-1A36-4E19-80CA-F66784E53476\_6\_en-US**

**DOI: [https://doi.org/10.31003/USPNF\\_M68470\\_06\\_01](https://doi.org/10.31003/USPNF_M68470_06_01)**

**DOI ref: [fhh11](#)**

OFFICIAL